(redirected from oropharyngeal candidiasis)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.
Related to oropharyngeal candidiasis: Cryptococcal Meningitis, Oral candidiasis


Infection with a fungus of the genus Candida, especially C. albicans, that usually occurs in the skin and mucous membranes of the mouth, respiratory tract, or vagina but may invade the bloodstream, especially in immunocompromised individuals. Also called candidosis, moniliasis.


(Medicine) another name for thrush21a


(ˌkæn dɪˈdaɪ ə sɪs)

n., pl. -ses (-ˌsiz)
any of a variety of infections caused by fungi of the genus Candida, occurring most often in the mouth, respiratory tract, or vagina. Compare thrush 2 (def. 1).
[1945–50; < New Latin Candid(a) + -iasis]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.candidiasis - an infection caused by fungi of the genus Monilia or Candida (especially Candida albicans)candidiasis - an infection caused by fungi of the genus Monilia or Candida (especially Candida albicans)
Candida albicans, Monilia albicans - a parasitic fungus that can infect the mouth or the skin or the intestines or the vagina
fungal infection, mycosis - an inflammatory condition caused by a fungus
thrush - candidiasis of the oral cavity; seen mostly in infants or debilitated adults
vaginitis - inflammation of the vagina (usually associated with candidiasis)


n candidiasis f, infección f por hongos or levaduras
References in periodicals archive ?
The company said Sitavig and Loramyc are the two first products developed and registered in Europe and the US by Onxeo R&D teams for the treatment of labial herpes and oropharyngeal candidiasis.
The approved indications for this triazole antifungal agent are prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, as well as treatment of oropharyngeal candidiasis.
It also reviews key players involved in the therapeutic development for Oropharyngeal Candidiasis and special features on late-stage and discontinued projects.
13) Oropharyngeal candidiasis (OPC) continues to be a common opportunistic infection in patients with HIV & is predictive of increasing immuno-suppression.
They increase the risk of pneumonia, oropharyngeal candidiasis, and bruising (SOR: B, meta-analyses of secondary outcomes).
Similarly, a throat infection with fungi (candida or "yeast") sometimes can also cause throat infection pain difficulty swallowing and white patches inside the mouth this throat infection commonly called Candidiasis, oropharyngeal candidiasis or thrush.
While the main indication is prophylaxis of fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome receiving remissioninducing therapy as well as transplant recipients of allogeneic hematopoietic stem cells with chronic graft-versus-host disease, the triazole treatment is also indicated as a rescue treatment in several fungal infections, including oropharyngeal candidiasis.
NOXAFIL also is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.
Epstein JB, Freilich MM, Le ND: Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck.
Oropharyngeal candidiasis (OPC) occurs in up to 90 per cent of HIV infected cases during the course of infection (1) and is considered as an important marker of the disease and its progression.